- Home
- ADAP vs NCSM Comparison
ADAP vs NCSM Comparison
Compare ADAP & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- NCSM
- Stock Information
- Founded
- ADAP 2008
- NCSM 2006
- Country
- ADAP United Kingdom
- NCSM United States
- Employees
- ADAP N/A
- NCSM N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- ADAP Health Care
- NCSM Energy
- Exchange
- ADAP Nasdaq
- NCSM Nasdaq
- Market Cap
- ADAP 75.5M
- NCSM 81.3M
- IPO Year
- ADAP 2015
- NCSM 2017
- Fundamental
- Price
- ADAP $0.29
- NCSM $29.26
- Analyst Decision
- ADAP Buy
- NCSM
- Analyst Count
- ADAP 6
- NCSM 0
- Target Price
- ADAP $1.52
- NCSM N/A
- AVG Volume (30 Days)
- ADAP 1.6M
- NCSM 8.1K
- Earning Date
- ADAP 05-13-2025
- NCSM 04-30-2025
- Dividend Yield
- ADAP N/A
- NCSM N/A
- EPS Growth
- ADAP N/A
- NCSM N/A
- EPS
- ADAP N/A
- NCSM 3.27
- Revenue
- ADAP $179,639,000.00
- NCSM $168,704,000.00
- Revenue This Year
- ADAP N/A
- NCSM $7.22
- Revenue Next Year
- ADAP $52.49
- NCSM $5.43
- P/E Ratio
- ADAP N/A
- NCSM $8.96
- Revenue Growth
- ADAP 878.53
- NCSM 18.16
- 52 Week Low
- ADAP $0.20
- NCSM $15.90
- 52 Week High
- ADAP $1.48
- NCSM $38.95
- Technical
- Relative Strength Index (RSI)
- ADAP 53.94
- NCSM 42.78
- Support Level
- ADAP $0.26
- NCSM $31.12
- Resistance Level
- ADAP $0.30
- NCSM $31.43
- Average True Range (ATR)
- ADAP 0.03
- NCSM 1.38
- MACD
- ADAP 0.00
- NCSM -0.31
- Stochastic Oscillator
- ADAP 58.12
- NCSM 0.00
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.